Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Heilig, Christoph E  [Clear All Filters]
2024
Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers S-T, Borchert S, Costa PFragoso, Schaarschmidt BM, Kessler L, et al. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024.
Rheinnecker M, Fröhlich M, Rübsam M, Paramasivam N, Heilig CE, Fröhling S, Schlenk RF, Hutter B, Hübschmann D. ZygosityPredictor. Bioinform Adv. 2024;4(1):vbae017.
2023
Lauinger M, Christen D, Klar RFU, Roubaty C, Heilig CE, Stumpe M, Knox JJ, Radulovich N, Tamblyn L, Xie IY, et al. BRAF in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability. Sci Adv. 2023;9(35):eade7486.
Scherr A-L, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, et al. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma. Hepatology. 2023.
2022
Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, et al. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022;172:107-118.
2020
Hübschmann D, Jopp-Saile L, Andresen C, Krämer S, Gu Z, Heilig CE, Kreutzfeldt S, Teleanu V, Fröhling S, Eils R, et al. Analysis of Mutational Signatures with YAPSA (Yet Another Package for Signature Analysis). Genes Chromosomes Cancer. 2020.
Voronina N, Wong JKL, Hübschmann D, Hlevnjak M, Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A, Stenzinger A, et al. The landscape of chromothripsis across adult cancer types. Nat Commun. 2020;11(1):2320.